相关临床试验
198
45 进行中
药物批准
22
批准总数
监管机构
1
监管机构数
成立时间
1882
进行中（未招募）
10
5.0%
已完成
91
46.0%
尚未招募
35
17.7%
招募中
42
21.2%
终止
8
4.0%
Unknown
10
5.0%
撤回
2
1.0%
- The PUMA trial, led by Monash University's Victorian Heart Institute, will compare pulmonary artery catheters and central venous catheters in 2,000 heart surgery patients to determine optimal monitoring approaches. - Researchers aim to reduce unnecessary treatments, shorten ICU stays, and cut healthcare costs by potentially adopting less invasive monitoring methods for the 20,000 Australians undergoing open heart surgery annually. - The study addresses decades of international controversy around pulmonary artery catheters, which have been de-adopted in other high-risk patient groups due to lack of proven benefits. - Patient co-design principles guided the trial development, with cardiac surgery survivor Paige Druce serving as a lived-experience investigator to ensure research priorities align with patient needs.
- BioNTech has partnered with Peter MacCallum Cancer Centre to establish a clinical trial platform in Victoria, Australia, aimed at improving access to investigational therapies for hard-to-treat cancers. - The platform creates a network of key delivery partners including Austin Health, Alfred Health, and Monash Health to streamline clinical trials across Melbourne and regional Victoria. - BioNTech is also establishing a state-of-the-art facility in Victoria in partnership with mRNA Vic to support research, development, and clinical-scale manufacturing of mRNA-based medicines. - The initiative leverages Victoria's thriving biomedical ecosystem and world-class cancer survival rates to potentially unlock breakthrough cancer treatments.
- Ribociclib (Kisqali) is now subsidized on Australia's Pharmaceutical Benefits Scheme for early-stage breast cancer patients with hormone receptor-positive, HER2-negative disease at high risk of recurrence. - The NATALEE trial demonstrated that adding ribociclib to standard hormone therapy reduced cancer recurrence risk by 28.5% compared to hormone therapy alone in 5,101 patients. - The PBS listing saves patients over $140,000 in treatment costs, as the drug previously cost approximately $3,700-$4,000 per month for three years without subsidy. - This development provides treatment options for approximately 70% of early-stage breast cancer cases, representing the most common subtype of the disease.
